

Utz Samuel (Orcid ID: 0000-0002-8794-6995)  
Borradori Luca (Orcid ID: 0000-0003-0424-6297)

## Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus

S. Utz<sup>1</sup>, V.G.A. Suter<sup>2</sup>, S. Cazzaniga<sup>1,3</sup>, L. Borradori<sup>1</sup>, L. Feldmeyer<sup>1</sup>

<sup>1</sup> Department of Dermatology, Inselspital Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland

<sup>2</sup> Department of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, CH-3010 Bern, Switzerland

<sup>3</sup> Centro Studi GISED, 24121 Bergamo, Italy

Corresponding author: Samuel Utz, Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland

Telephone: +41 (0)79 922 62 72; Fax: +41 (0)31 632 22 33;

Email: samuel.utz@bluewin.ch

**Funding sources:** None

**Conflicts of interest:** None declared

**IRB approval status:** Reviewed and approved by the ethics committee of the Canton of Bern (KEK-2020-02577).

**Availability of data:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy/ethical restrictions.

**Patient privacy:** The patients in this manuscript have given written informed consent to publication of their case details.

Word number: 2995

Tables number: 2 (+ 2 supplementary)

Figures number: 3

References: 45

### Key words

Oral lichen planus, topical tacrolimus, long-term outcome

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/jdv.18457](https://doi.org/10.1111/jdv.18457)

This article is protected by copyright. All rights reserved.

## Abbreviations

CI: confidence interval, CR: complete remission, MR: major remission, OLP: oral lichen planus, PR: partial remission, RCT: randomized controlled trial, SCC: squamous cell carcinoma

## Abstract

**Background and Objective:** Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme.

**Methods:** Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission, no response), subjective impairment by a 3-point scale (severe, moderate, none).

**Results:** Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months, respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment, respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months, respectively. 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developed a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects.

**Conclusion:** Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.

## Introduction

Lichen planus is a mucocutaneous inflammatory disease involving mainly the skin and the oral mucosa. Other mucosae (genital, esophageal, conjunctival), hair follicles and nails can also be affected.<sup>1-3</sup> Oral lichen planus (OLP) shows a female predominance and an overall prevalence between 1 and 2%.<sup>4</sup>

While the most frequent reticular form of OLP is mostly asymptomatic and does not require treatment, the erosive form is often associated with disabling pain resulting in a substantially reduced quality of life, malnutrition and weight loss.<sup>1-3,5</sup> Since effective therapeutic options are limited, the management of OLP remains challenging.<sup>6-9</sup> First-line treatment of OLP consists of topical corticosteroids. In patients with a refractory course, topical calcineurin-inhibitors like tacrolimus, pimecrolimus and cyclosporine are recommended.<sup>6-9</sup> The beneficial effect of topical tacrolimus has been demonstrated in numerous previous studies.<sup>10-20</sup> However, the follow-up was too short to evaluate the long-term outcome. Specifically, the impact of a gradual reduction of the application frequency and treatment cessation have not been investigated.

We therefore analysed the clinical response of OLP to tacrolimus in daily clinical practice with a focus on the optimal therapeutic application scheme and possible reduction over time as well as adverse reactions including malignant transformation.

## Methods

This study includes all fifty-seven consecutive patients of the Department of Dermatology at the University Hospital of Bern and the Department of Oral Surgery and Stomatology (in a joint consultation of LF and VS) diagnosed with OLP according to the clinical and histopathological criteria of the WHO<sup>21</sup> and treated with topical tacrolimus between 01.01.2015 and 01.10.2020 after treatment failure under potent topical corticosteroids. The patients were instructed to perform a 5-min mouthwash with a magistral preparation of 0.03% tacrolimus solution (solution: sodium carboxymethylcellulose 1%, methyl parahydroxybenzoate 0.07%, propyl parahydroxybenzoate 0.03%, distilled water 98.9%).

The clinical OLP subtype was classified as either only hyperkeratotic (all non-erosive subforms), both erosive/hyperkeratotic or only erosive. Clinical remission was evaluated using the following 4-point scale: CR (complete remission): regression of all visible oral lesions; MR (major remission): regression of >50% of the lesions; PR

(partial remission): regression of 25-50% of the lesions; no response (<25% regression). In addition, subjective impairment was assessed using a 3-point scale: severe (compromised food intake), moderate or no impairment. Further evaluated parameters were adjustments of the therapy regimen at every follow-up, adjuvant treatment, malignant transformation and adverse drug reactions.

### **Statistical analysis**

For descriptive purposes, continuous data were presented as medians with ranges, while categorical data were reported as absolute numbers with percentages. A discrete longitudinal analysis was performed by categorizing available visits around pre-defined time points: 0 (baseline), 3, 6, 9, 12, 24, 36, 48 and 60 months. More specifically, the first closest visit around each time point was retained in the discrete analysis. Patients without an available visit within the interval considered were not included in this analysis. Tests for linear trend of different outcomes changes across visits were performed by using generalized estimating equations (GEEs) with binomial or multinomial distributions, assuming an exchangeable correlation structure.

The Kaplan-Meier estimator was used to calculate cumulative probabilities for the incidence of specific outcomes at follow-up. Incidence estimates were calculated along with their 95% confidence intervals (CI). The median times to the first event were computed as well and presented with their 95% CI.

Cohen's kappa was used to compute the degree of concordance between objective vs subjective improvement at follow-up and presented with its 95% CI. All tests were considered statistically significant at p-value <0.05. Analyses were carried out with SPSS software v.26 (IBM Corp, Armonk, NY, US).

## **Results**

### **Clinical characteristics**

The demographic and clinical characteristics of the enrolled patients are presented in Table 1. Fifty-seven patients were included, 42 women and 15 men (ratio M : F = 1 : 2.8) with a median age at baseline of 66 years (range: 33-90 years). Forty-six (80.7%) patients showed a combination of hyperkeratotic and erosive lesions of OLP, 7 (12.3%) only hyperkeratotic and 4 (7%) only erosive lesions. The buccal mucosa was the most commonly affected intraoral localization in 52 (91.2%), followed by the gingiva in 42 (73.7%) cases, but the majority showed multiple affected sites. An extraoral involvement was documented in 15 patients (26.3%).

Before the initiation of tacrolimus, 56 patients (98.2%) were treated with potent topical steroids – either betamethasone mouth rinse (betamethasone dihydrogenphosphate-disodium water-soluble tablets 0.5 mg, commercially available, in 1dl water) or fluocinonide gel 0.05%, commercially available. Systemic corticosteroids and doxycycline were concomitantly given in three (5.3%) and one (1.8%) patients, respectively. One patient (1.8%) was given tacrolimus as first-line. The median duration of the prior therapy was 4 months (range: one month to 14 years). The median follow-up duration was 19.6 months, ranging from 2.1 to 66.5 months.

### **Clinical response to treatment**

The objective therapeutic response to topical tacrolimus is visualized in Fig. 1. Clinical remission was evaluated after 3, 6, 9, 12, 24, 36 and 60 months. Four patients (7.0%) were lost to follow-up in the first 3 months. After three months of treatment the cumulative number of patients who reached objective remission (CR or MR) was 16 (estimated cumulative incidence: 28.4%; 95% CI: 16.6-40.2), 33 (62.2%; 95% CI: 48.9-75.5) after 6 months, 44 (88.3%; 95% CI: 78.3-98.3) after 12 and 47 (97.1; 95% CI: 91.6-100) after 24 months. The median time to first objective remission was 4.4 months (95% CI: 3.3-5.5).

Complete remission was seen in no patient at month 3, in 3 patients (cumulative incidence 6%; 95% CI: 0-12.8) at month 6, 4 (8.5%; 95% CI: 0.5-16.5) at month 12 and 5 (11.7%; 95% CI: 1.9-21.5) at month 24.

Among the 49 patients who reached objective remission at some point during the study period, the cumulative number of clinical relapses (any objective decline after initial improvement >50%) was 7 (cumulative incidence: 16.5%; 95% CI: 5.3-27.7) at month 6, 12 (30.4%; 95% CI: 15.9-44.9) at month 12 and 15 (41.3%; 95% CI: 24.4-58.2) at month 24. The median time to relapse after reaching objective remission was 27.2 months (95% CI: 17.1-37.4).

### **Subjective improvement**

The subjective therapeutic response is presented in Fig. 2. Overall, 56 of 57 (98.2%) patients reported an initial improvement on tacrolimus. Before initiation of therapy, 42 patients (73.7%) reported a severe impairment with compromised food intake. Ten patients (17.5%) had moderate symptoms, while 5 (8.8%) specified no subjective impairment. After three months the cumulative number of patients reaching subjective remission (no impairment) was 9 (cumulative incidence: 15.9%; 95% CI: 6.3-25.5), 26 (48.0%; 95% CI: 34.7-61.3) after 6 months, 37 (70.9%; 95% CI: 58.2-83.6) after 12 and 42 (84.9%; 95% CI: 73.7-96.1) after 24 months. The median time to first subjective remission was 6.3 months (95% CI: 4.4-8.2).

Comparing the two parameters of objective and subjective remission, Cohen's kappa was 0.42 (95% CI: 0.33-0.51), representing an only moderate agreement.

### **Adaptation of treatment frequency**

The initial dosage of the tacrolimus oral rinse was twice daily for 5 minutes. Two patients (3.5%) started with 3 times daily and 6 (10.5%) with once daily. In case of an objective clinical remission and impairment reduction, the treatment frequency was gradually reduced. The respective percentages of the frequencies at each cut off point are displayed in Fig. 3. After three months, 28.4% of the patients were able to use the oral rinse once daily or less, after 6 months 60.5%, after 12 months 77.5% and after 24 month 86.7%. Cases with a clinical relapse were managed by a re-increase of application frequency.

The cumulative number of patients who once completely suspended the treatment during the evaluated time period was 17 (cumulative incidence: 41.2%; 95% CI: 24.7-57.7). Among these, 12 patients continued to be followed-up and 7 (estimated cumulative incidence: 75.1%; 95% CI: 45.9-100) restarted the treatment after a median time of 3.2 months (95% CI: 2.3-4.1) because of a recrudescence of clinical signs.

### **Adjuvant treatment**

Because of an insufficient disease control on topical tacrolimus, treatment escalation was necessary in 7 cases (12.3%), which were excluded from the final analysis after this point. Five patients (8.7%) received additional systemic corticosteroids, 2 of them in combination with topical retinoids, while the other 2 were given methotrexate.

### **Side-effects**

A total of 5 patients (8.7%) reported side-effects: two patients (3.5%) had a burning sensation, two (3.5%) presented with dysgeusia, while one (1.8%) had nausea. Except for the latter case which resulted in discontinuation of therapy, there was no interference with the treatment protocol.

### **Malignant transformation**

During the whole observation period of this study, 4 patients (7%) were diagnosed with a squamous cell carcinoma (SCC) of the oral mucosa. They were 2 women and 2 men with a median age of 80 years (range: 59-82 years). Characteristics and treatment are presented in Table 2. All were diagnosed in an early stage (pTis, pT1). One patient (Table 2, Nr. 4) had a history of SCC on the tongue 4 years before initiation of tacrolimus, while another (Table 2, Nr. 1) was diagnosed with two simultaneous SCC in different localizations during the study period. The median duration of tacrolimus use was 20.5 months (range: 1-36 months) until diagnosis of the oral SCC; in one patient (Table 2, Nr. 2) – with 30 pack years – this was only one month. Three patients continued with tacrolimus after the oncologic-surgical intervention while one stopped.

### **Loss to follow-up**

The cumulative number of patients lost to follow-up was 19 (cumulative incidence: 33.3%; 95% CI: 21.1-45.5) after 12 months, 32 (56.1%; 95% CI: 43.2-69.0) after 24 and 44 (77.2%; 95% CI: 66.2-88.2) after 36, 49 (86.0%; 95% CI: 77.0-95.0) after 48, and 52 (91.2%; 95% CI: 83.9-98.5) after 60 months.

### **Discussion**

The treatment of OLP can be challenging for both affected patients and treating physicians. An effective therapy is essential for pain relief, improvement of quality of life as well as risk reduction for malignant transformation. If potent or super-potent topical corticosteroids as first-line treatment do not entail a sufficient improvement, the calcineurin inhibitor tacrolimus can be a valuable and effective alternative to treat OLP.<sup>10-20,22,23</sup>

The efficacy of topical calcineurin inhibitors in comparison to topical corticosteroids has been examined in four conventional meta-analyses. While three studies concluded that both therapies are similarly effective<sup>17,18,24</sup>, one report indicated that topical tacrolimus is superior compared to topical steroids.<sup>16</sup> In a meta-analysis of multiple interventions,

tacrolimus showed the best clinical response and the best symptom-reducing effect when compared to placebo and other topical interventions, while dexamethasone had the best sign-reducing effect and showed the least adverse events.<sup>19</sup> However, the overall evidence is of low level and the most recent Cochrane review concluded that although topical tacrolimus may be more effective in terms of subjective pain relieve, the differences concerning objective clinical response and adverse effects were uncertain and partially conflicting.<sup>25</sup>

In our department, the use of topical tacrolimus as second-line treatment for OLP has been conducted for more than a decade as well as clinically evaluated.<sup>13</sup> Consequently, our follow-up with 66.5 months (median 19.6 months) is longer than all previously published studies regarding OLP treatment with tacrolimus. The 0.03% oral mouthwash formulation was used based on our previously observed beneficial results.<sup>13</sup> The latter implied sufficient local bioavailability with a positive effect on the mucosal inflammatory process. The utilized 0.03% concentration further minimized the risk of systemic absorption. Finally, the oral mouthwash was preferred to the commercial 0.03 % or 0.1% tacrolimus ointment by the patients because of its much easier use and better subjective tolerability with less irritation and burning sensation.

Compared to other studies, the clinical characteristics of the patients included in our study were congruent, with a female predilection and a median age in the sixth decade.<sup>2,4,7</sup> Erosive lesions were found in 87.7% which is similar to other studies who included only recalcitrant symptomatic OLP patients<sup>12,13,20,26</sup>, but significantly higher than the overall OLP population, in which 32.5% of cases show an erosive variant.<sup>4</sup> Both the objective and subjective remission showed no significant association with any baseline parameter as sex, age, OLP subtype, localization, prior treatments or their duration.

Since complete remission (CR) was defined as a complete absence of visible lesions, only very few patients met this condition due to persistent reticular alterations of the oral mucosa. Most patients belong therefore to the major remission (MR) group, with a positive therapy response and no remaining erosions. Consequently, our CR rate of 0% at month 3, 6.1% at month 6 and 8.5% at month 12 is significantly lower than in most previous studies with reported CR rates ranging from 14% up to 59.5%.<sup>12,13,20,26</sup> However, by pooling both CR and MR as clinical remission with no erosive lesions, we



observed clinical remission in 28.4% after 3 months, 62.2% after 6 and 88.3% after 12 months of treatment.

A similar retrospective analysis of topical tacrolimus in OLP was pursued in four other previous studies: One study of 13 patients using either 0.03% mouthwash or 0.1%/0.3% ointment found complete remission in 23% and partial response and 62% after 8 weeks.<sup>27</sup> Another study with 37 patients receiving either 0.03% or 0.1% ointment described 84% partial to complete response after 6 months, whereas in another report 91.3% of 23 patients using 0.1% ointment achieved clinical improvement after 6 weeks.<sup>12,26</sup> In our previous study in which 0.03% mouthwash was used, we observed a complete remission in 19% and 33% of 21 patients, while a partial or major response was found in 48% and 50% of cases after 2 and 6 months, respectively.<sup>13</sup>

Two prospective analyses reported a complete or partial response in 95% of 40 enrolled patients and 80% of 15 patients after both 2 months, while another report noted a significant clinical improvement in 75% of 20 patients who received tacrolimus 0.1% ointment over 3 months.<sup>28-30</sup> In addition, Hodgson et al. examined 50 patients in a prospective study with a follow-up of 2-39 months (median: 19.8 months). Complete resolution, partial response and no response were noted in 14%, in 80% and in 6% of cases, respectively.<sup>20</sup>

However, the clinical and methodological heterogeneity across these various studies makes any comparison difficult.

Our observed initial subjective improvement rate under therapy of 98.2% is in line with the findings of two other studies, in which subjective improvement was noted in 100% and 89% of cases.<sup>12,16</sup> However, a substantial number of our patients continuously reported moderate symptoms. Therefore, subjective remission (no impairment) was only achieved in 15.9% after 3 months of therapy. Noteworthy, this rate improved over time with 48% after 6 and 70.9% after 12 months.

An interesting observation is the discordance between the objective and subjective improvement. With a Cohen's kappa of 0.42 (95% CI 0.33-0.51), the two parameters only showed a moderate agreement. Consequently, the clinical image did not necessarily correlate to the level of pain. This variation in individual perception underlines the importance of considering both the subjective improvement as well as clinical remission as treatment objectives.

The cumulative recurrence rate of 75.1% after complete cessation of tacrolimus in 17 patients is similar to previous studies describing 50% up to 76.5%.<sup>11,12,26,31–33</sup>

Only a small group of 5 patients (8.7%) reported adverse effects over the whole observation period, except for one case with therapy limiting nausea, all being minor like burning sensation and dysgeusia. This is in contrast to previous studies which noted much higher rates of side-effects<sup>12,28,33</sup>, but used 0.1% tacrolimus ointment.

We identified a SCC in 4 patients (7.0%), while the estimated overall incidence of malignant transformation for OLP is 1.37%.<sup>34</sup> This comparatively high rate might indicate a direct causality between prolonged use of tacrolimus and development of SCC, as it has been claimed in previous case reports.<sup>35,36</sup> However, malignant transformation varies considerably among studies and the real risk related to OLP or its treatment remains unknown.<sup>34,35,37–39</sup> Chronic inflammation as a cause of carcinogenesis has been demonstrated in various diseases, possibly explaining why patients with erosive forms of OLP more often show a malignant transformation.<sup>34,37,39</sup> Similarly, our cohort consisted of patients referred to a tertiary center with an already more severe and chronic disease, including 87.7% with an erosive form of OLP, suggesting that they were overall more at risk for SCC.<sup>34</sup> Furthermore, one patient with 30 years of nicotine abuse was diagnosed only one month after initiation of tacrolimus, while another one already had a history of SCC.

Altogether, there is currently no sound evidence indicating that tacrolimus affects the inherent risk of OLP for malignant transformation, although this possibility cannot be excluded.<sup>35,36,38–40</sup> In this context, a recent meta-analysis did not find an association between the use of topical calcineurin inhibitors and an increased risk of keratinocyte carcinomas.<sup>41</sup> Another study even postulated a significantly lower risk for oral carcinogenesis under tacrolimus through cell cycle control via induction of G1/S phase arrest and therefore inhibition of epithelial cell proliferation and tumour formation.<sup>42</sup> Nonetheless, also based on the observed high rate of malignancies in our series, regular follow-up of patients with erosive OLP during treatment remains fundamental to recognize malignant transformation in an early stage.

The major limitation of this study is its retrospective design with no control group and accordingly no systematic follow-up. The used 0.03% tacrolimus rinse may limit direct comparison to other studies with different preparations. Furthermore, measurement of tacrolimus serum levels was not part of the study protocol. The substantial loss to follow-up is explained by the referral for further supervision by family doctors or dentists after clinical improvement. To better characterize the efficacy and the optimal long-term therapeutic scheme of topical tacrolimus in OLP management as well as to determine a cause-effect relationship of tacrolimus and malignant transformation, a large prospective RCT with a systematic follow-up remains necessary.

### **Conclusion**

Topical tacrolimus can be a valuable option as a second-line treatment for OLP refractory to potent topical corticosteroids. Once OLP is satisfactorily controlled with twice daily tacrolimus mouthwash, the frequency can be reduced to a maintenance therapy aimed at preventing relapses. Both signs of clinical activity as well as subjective discomfort and pain should guide therapy. Complete discontinuation is possible in a minority of patients. Regular follow-up is mandatory to recognize malignant transformation in early stage.

## References

1. Au J, Patel D, Campbell JH. Oral lichen planus. *Oral Maxillofac Surg Clin North Am* 2013;**25**:93–100, vii.
2. Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2016;**122**:72–80.
3. Carrozzo M, Porter S, Mercadante V, Fedele S. Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorithms, prognosis, management strategies. *Periodontol 2000* 2019;**80**:105–25.
4. González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, et al. Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. *Oral Dis* 2021;**27**:813–28.
5. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. *N Engl J Med* 2012;**366**:723–32.
6. Gupta S, Ghosh S, Gupta S. Interventions for the management of oral lichen planus: a review of the conventional and novel therapies. *Oral Dis* 2017;**23**:1029–42.
7. García-Pola MJ, González-Álvarez L, Garcia-Martin JM. Treatment of oral lichen planus. Systematic review and therapeutic guide. *Med Clin (Barc)* 2017;**149**:351–62.
8. Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. *Cochrane Database Syst Rev* 2011;:CD001168.
9. Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions for treating oral lichen planus: a systematic review. *Br J Dermatol* 2012;**166**:938–47.
10. Elad S, Epstein JB, Yarom N, Drucker S, Tzach R, von Bültzingslöwen I. Topical immunomodulators for management of oral mucosal conditions, a systematic review; part I: calcineurin inhibitors. *Expert Opin Emerg Drugs* 2010;**15**:713–26.
11. Eckardt A, Völker B, Starke O, Kaefer V, Kapp A. Topical tacrolimus in erosive oral lichen planus: An effective treatment approach. *Oral Biosci Med* 2005;**4**.
12. Byrd JA, Davis MDP, Bruce AJ, Drage LA, Rogers RS. Response of oral lichen planus to topical tacrolimus in 37 patients. *Arch Dermatol* 2004;**140**:1508–12.
13. Ribero S, Stieger M, Quaglino P, et al. Efficacy of topical tacrolimus for oral lichen planus: real-life experience in a retrospective cohort of patients with a review of the literature. *J Eur Acad Dermatol Venereol* 2015;**29**:1107–13.
14. Sotoodian B, Lo J, Lin A. Efficacy of Topical Calcineurin Inhibitors in Oral Lichen Planus. *J Cutan Med Surg* 2015;**19**:539–45.
15. Samyia M, Lin AN. Efficacy of topical calcineurin inhibitors in lichen planus. *J Cutan Med Surg* 2012;**16**:221–9.
16. Chamani G, Rad M, Zarei MR, Lotfi S, Sadeghi M, Ahmadi Z. Efficacy of tacrolimus and clobetasol in the treatment of oral lichen planus: a systematic review and meta-analysis. *Int J Dermatol* 2015;**54**:996–1004.
17. Guo C, Zhao J, Zhang J, Dong H. Efficacy of Topical Tacrolimus for Erosive Oral

Lichen Planus: A Meta-analysis. *Chin Med Sci J* 2015;**30**:210–7.

18. Sun S-L, Liu J-J, Zhong B, *et al.* Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis. *Br J Dermatol* 2019;**181**:1166–76.

19. Yuan P, Qiu X, Ye L, *et al.* Efficacy of topical administration for oral lichen planus: A network meta-analysis. *Oral Dis* 2021.

20. Hodgson TA, Sahni N, Kaliakatsou F, Buchanan JAG, Porter SR. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. *Eur J Dermatol* 2003;**13**:466–70.

21. Rad M, Hashemipoor MA, Mojtahedi A, *et al.* Correlation between clinical and histopathologic diagnoses of oral lichen planus based on modified WHO diagnostic criteria. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009;**107**:796–800.

22. Siponen M, Huuskonen L, Kallio-Pulkkinen S, Nieminen P, Salo T. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. *Oral Dis* 2017;**23**:660–8.

23. Hettiarachchi PVKS, Hettiarachchi RM, Jayasinghe RD, Sittheequ M. Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double-blinded, randomized clinical trial in Sri Lanka. *J Investig Clin Dent* 2017;**8**.

24. Su Z, Hu J, Cheng B, Tao X. Efficacy and safety of Topical Administration of Tacrolimus in Oral Lichen Planus: an updated systematic review and meta-analysis of randomized controlled trials. *J Oral Pathol Med* 2021.

25. Lodi G, Manfredi M, Mercadante V, Murphy R, Carrozzo M. Interventions for treating oral lichen planus: corticosteroid therapies. *Cochrane Database Syst Rev* 2020;**2**:CD001168.

26. Thomson MA, Hamburger J, Stewart DG, Lewis HM. Treatment of erosive oral lichen planus with topical tacrolimus. *J Dermatolog Treat* 2004;**15**:308–14.

27. Rozycki TW, Rogers RS, Pittelkow MR, *et al.* Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. *J Am Acad Dermatol* 2002;**46**:27–34.

28. Vohra S, Singal A, Sharma SB. Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial. *Int J Dermatol* 2016;**55**:101–5.

29. Sonthalia S, Singal A. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial. *Int J Dermatol* 2012;**51**:1371–8.

30. Resende JPM, Chaves M das GAM, Aarestrup FM, Aarestrup BV, Olate S, Netto HD. Oral lichen planus treated with tacrolimus 0.1%. *Int J Clin Exp Med* 2013;**6**:917–21.

31. Arduino PG, Campolongo MG, Sciannameo V, *et al.* Randomized, placebo-

controlled, double-blind trial of clobetasol propionate 0.05% in the treatment of oral lichen planus. *Oral Dis* 2018;**24**:772–7.

32. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. *J Am Acad Dermatol* 2002;**46**:35–41.

33. Kiyani A, Sohail K, Saeed MHB. Efficacy of 0.1% tacrolimus in long-term management of erosive lichen planus. *J Dermatolog Treat* 2021;**32**:367–71.

34. Giuliani M, Troiano G, Cordaro M, *et al.* Rate of malignant transformation of oral lichen planus: A systematic review. *Oral Dis* 2019;**25**:693–709.

35. Mattsson U, Magnusson B, Jontell M. Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010;**110**:e19-25.

36. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. *Br J Dermatol* 2003;**149**:960–7.

37. Aghbari SMH, Abushouk AI, Attia A, *et al.* Malignant transformation of oral lichen planus and oral lichenoid lesions: A meta-analysis of 20095 patient data. *Oral Oncol* 2017;**68**:92–102.

38. Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. *J Am Dent Assoc* 2014;**145**:45–56.

39. Georgakopoulou EA, Ahtari MD, Ahtaris M, Foukas PG, Kotsinas A. Oral lichen planus as a preneoplastic inflammatory model. *J Biomed Biotechnol* 2012;**2012**:759626.

40. Ribero S, Borradori L. Re: risk of malignancy and systemic absorption after application of topical tacrolimus in oral lichen planus. *J Eur Acad Dermatol Venereol* 2017;**31**:e85–6.

41. Lam M, Zhu JW, Tadrous M, Drucker AM. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis. *JAMA Dermatol* 2021;**157**:549–58.

42. Li Y, Wang Y, Li J, *et al.* Tacrolimus inhibits oral carcinogenesis through cell cycle control. *Biomed Pharmacother* 2021;**139**:111545.

**Legend:**

Figure 1: Grade of remission at follow-up

Figure 2: Judge on impairment at follow-up

Figure 3: Therapy frequency at baseline and follow-up

**Table 1** – Clinical characteristics of patients included in the study (N = 57)

		N=57	%
Sex	Female	42	73.7%
	Male	15	26.3%
Age at therapy start	Median, years (Range; IQR)		66 (33-90; 55-75)
Predominant form	Only hyperkeratotic	7	12.3%
	Hyperkeratotic/erosive	46	80.7%
	Only erosive	4	7.0%
Localization*	Buccal mucosa	52	91.2%
	Gingiva	42	73.7%
	Tongue	22	38.6%
	Lips	9	15.8%
	Palate	7	12.3%
Extraoral involvement*	None	42	73.7%
	Genital	9	15.8%
	Cutaneous	8	14.0%
	Hair follicles	1	1.8%
	Esophageal	1	1.8%
Previous therapy*	None	1	1.8%
	Topical steroids	55	96.5%
	Systemic steroids	3	5.3%
	Doxycycline	1	1.8%
Duration of prior therapy	Median, months (Range; IQR)		4.0 (1.0-168.0; 2.0-6.0)
Length of follow-up	Median, months (Range; IQR)		19.6 (2.1-66.5; 8.5-33.2)
Malignant transformation		4	7.0%

IQR: interquartile range

\* Multiple locations/involvements/therapies were possible




**Table 2** – Clinical characteristics of the four patients with an oral squamous cell carcinoma (SCC)

Patient	Sex	Age (years)	Smoking	Stage of SCC	Intraoral localization of SCC	Duration in month of Tacrolimus application	Treatment of SCC
1	F	82	never	pT1 cN0 cMo pT1 cN0 cMo	- Gingiva - Palate	24	Tumor resection Neck dissection
2	M	59	former (30 py)	pT1 cN0 cMo	Tongue border	1	Tumor resection Neck dissection Radiotherapy
3	M	80	never	pTis cN0 cMo	Oral vestibule	17	Resection
4	F	70	former (1 py)	pT1 cN0 cMo pTis*	- Gingiva - Tongue border -	36	Resection


Notes: F, female; M, male; py, pack years; c, clinical; p, post therapeutic;

T, Tumor size; Tis, in situ; T1, < 2 cm; T2, 2-4 cm; N, node; N0, none; N1, ipsilateral < 3cm; M, metastasis (distant); M0, none


\* History of pTis 4 years before initiation of tacrolimus



JDV\_18457\_jeadv-2021-3575-File004.png



JDV\_18457\_jeadv-2021-3575-File005.png



JDV\_18457\_jeadv-2021-3575-File006.png